Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.

Pazina T, James AM, Colby KB, Yang Y, Gale A, Jhatakia A, Kearney AY, Graziano RF, Bezman NA, Robbins MD, Cohen AD, Campbell KS.

Cancer Immunol Res. 2019 Oct;7(10):1633-1646. doi: 10.1158/2326-6066.CIR-18-0579. Epub 2019 Aug 20.

PMID:
31431433
2.

PD-1 blockade enhances elotuzumab efficacy in mouse tumor models.

Bezman NA, Jhatakia A, Kearney AY, Brender T, Maurer M, Henning K, Jenkins MR, Rogers AJ, Neeson PJ, Korman AJ, Robbins MD, Graziano RF.

Blood Adv. 2017 May 8;1(12):753-765. doi: 10.1182/bloodadvances.2017004382. eCollection 2017 May 9.

3.

ARF: connecting senescence and innate immunity for clearance.

Kearney AY, Anchang B, Plevritis S, Felsher DW.

Aging (Albany NY). 2015 Sep;7(9):613-5.

4.

8-Chloroadenosine Sensitivity in Renal Cell Carcinoma Is Associated with AMPK Activation and mTOR Pathway Inhibition.

Kearney AY, Fan YH, Giri U, Saigal B, Gandhi V, Heymach JV, Zurita AJ.

PLoS One. 2015 Aug 27;10(8):e0135962. doi: 10.1371/journal.pone.0135962. eCollection 2015.

5.

Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial.

Bilen MA, Zurita AJ, Ilias-Khan NA, Chen HC, Wang X, Kearney AY, Hodges S, Jonasch E, Huang S, Khakoo AY, Tannir NM.

Oncologist. 2015 Oct;20(10):1140-8. doi: 10.1634/theoncologist.2015-0143. Epub 2015 Aug 25.

Supplemental Content

Loading ...
Support Center